Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel CD33 antibodies unravel localization, biology and therapeutic implications of CD33 isoforms.

Future oncology (London, England) - 1 Jan 2021

Gbadamosi Mohammed O, Shastri Vivek M, Hylkema Tiffany, Papageorgiou Ioannis, Pardo Laura, Cogle Christopher R, Doty Andria, Loken Michael R, Meshinchi Soheil, Lamba Jatinder K

Abstract excerpt

The aim of this study was to establish the therapeutic relevance of the CD33D2 isoform by developing novel antibodies targeting the IgC domain of CD33. Two novel IgC-targeting antibodies, HL2541 and 5C11-2, were developed, and CD33 isoforms were assessed using multiple assays in cells overexpressing either CD33FL or CD33D2 isoforms, unmodified acute myeloid leukemia (AML) cell lines and primary AML specimens...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Bone Marrow Cells

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Child, Preschool

Share to Infant

Share to Leukemia, Myeloid, Acute

Share to Protein Isoforms

Share to Sialic Acid Binding Ig-like Lectin 3

Source

Open in PubMed Open full text

Identifiers

PMID: 33356566
DOI: 10.2217/fon-2020-0746
PMCID: PMC10621775

Genes

CD33

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel CD33 antibodies unravel localization, biology and therapeutic implications of CD33 isoforms.PMID 33356566Read ↗

Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemiaSemantic proximity Read ↗

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.Semantic proximity Read ↗

The CD33 splice isoform lacking exon 2 as therapeutic target in human acute myeloid leukemiaSemantic proximity Read ↗

CRISPR/Cas9 gene editing clarifies the role of CD33 SNP rs12459419 in gemtuzumab ozogamicin-mediated cytotoxicity.Semantic proximity Read ↗

Targeting CD33 for Acute Myeloid Leukemia TherapySemantic proximity Read ↗

CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.Semantic proximity Read ↗

Targeting CD33 for acute myeloid leukemia therapy.Semantic proximity Read ↗

Differences in CD33 Intensity Between Various Myeloid NeoplasmsSemantic proximity Read ↗

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemiaSemantic proximity Read ↗

High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation.Semantic proximity Read ↗

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.Semantic proximity Read ↗

CCGG deletion (rs201074739) in CD33 results in premature termination codon and complete loss of CD33 expression: another key variant with potential impact on response to CD33-directed agentsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.